Our integrated product platforms encompass gene editing and cancer immunotherapy – providing us with the potential to treat or cure a broad range of serious diseases.
Transform Expert Protocols into Clinical Data
Our objective is to develop and bring to market therapies based on the transformative potential of gene therapy as a one-time treatment option for patients with HIV/AIDS or cancer. Our pipeline is comprised of cell therapies and immunotherapies for HIV/AIDS and solid cancers. All products in our pipeline derive from our internal research and development. Therefore, we possess an extensive, international IP portfolio.